{"product_id":"tirzee-injection-2-5mg-0-5ml-1-box-1prefilled-pen","title":"Tirzee Injection 2.5MG\/0.5Ml (1 Box = 1Prefilled Pen)","description":"\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003cdiv id=\"SPECIFICATION\" class=\"productDescription_descriptionWrapper2__mjUHQ\"\u003e\n\u003ch2 class=\"MuiTypography-root MuiTypography-body1 productDescription_productTitle__lpzz8 css-9l3uo3\"\u003eTirzee Injection 2.5mg\/0.5ml (1 Box = 1Prefilled Pen) Specification\u003c\/h2\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eRequires Prescription (YES\/NO)\u003c\/h3\u003e\n\u003cp\u003eYes\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eGenerics\u003c\/h3\u003e\n\u003cp\u003eTirzepatide\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eUsed For\u003c\/h3\u003e\n\u003cp\u003eDiabetes Management\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eHow it works\u003c\/h3\u003e\n\u003cp\u003eTirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. It enhances first- and second-phase insulin secretion and reduces glucagon levels, both in a glucose-dependent manner . In addition, both GIP and GLP-1 receptors are expressed in the areas of the brain important to appetite regulation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"USAGE AND SAFETY\" class=\"productDescription_descriptionWrapper2__mjUHQ\"\u003e\n\u003ch2 class=\"MuiTypography-root MuiTypography-body1 productDescription_productTitle__lpzz8 css-9l3uo3\"\u003eUsage And Safety\u003c\/h2\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eDosage\u003c\/h3\u003e\n\u003cp\u003eThe starting dose of Tirzepatide is 2.5 mg once weekly. After 4 weeks, the dose should be increased to 5 mg once weekly . If needed, dose increases can be made in 2.5 mg increments after a minimum of 4 weeks on the current dose. Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage. The maximum dose is 15 mg once weekly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eSide Effects\u003c\/h3\u003e\n\u003cp\u003eVery common : Hypoglycemia when used with sulphonylurea or insulin, nausea, diarrhoea, vomiting, abdominal pain and constipation. Common : Hypersensitivity reactions, hypoglycaemia when used with metformin and SGLT2i, decreased appetite, dizziness, hypotension, dyspepsia, abdominal distention, flatulence, gastroesophageal reflux disease, hair loss, fatigue, injection site reactions, heart rate increased, lipase increased, amylase increased and blood calcitonin increased. Uncommon: Hypoglycaemia when used with metformin, weight decreased, dysgeusia, dysaesthesia, cholelithiasis, cholecystitis, acute pancreatitis, delayed gastric emptying and injection site pain. Rare: Anaphylactic reaction and angioedema.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eDrug Interactions\u003c\/h3\u003e\n\u003cp\u003eConcomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin : When initiating Tirzepatide, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia. Oral Medications : Tirzepatide delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with Tirzepatide. Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin, digoxin) when concomitantly administered with Tirzepatide. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with Tirzepatide. Hormonal contraceptives that are not administered orally should not be affected.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eIndication\u003c\/h3\u003e\n\u003cp\u003eType 2 Diabetes Mellitus : Tirzepatide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. Weight Management : Tirzepatide is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. Obstructive Sleep Apnea (OSA) : Tirzepatide is indicated in combination with a reduced-calorie diet and increased physical activity to treat moderate to severe Obstructive Sleep Apnea (OSA) in adults with obesity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eWhen not to Use\u003c\/h3\u003e\n\u003cp\u003eTirzepatide is contraindicated in patients with : Known serious hypersensitivity to Tirzepatide or to any of the excipients of the product. A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"PRECAUTIONS\" class=\"productDescription_descriptionWrapper2__mjUHQ\"\u003e\n\u003ch2 class=\"MuiTypography-root MuiTypography-body1 productDescription_productTitle__lpzz8 css-9l3uo3\"\u003ePrecautions\u003c\/h2\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003ePrecaution\u003c\/h3\u003e\n\u003cp\u003eTirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Tirzepatide and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Tirzepatide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"WARNINGS\" class=\"productDescription_descriptionWrapper2__mjUHQ\"\u003e\n\u003ch2 class=\"MuiTypography-root MuiTypography-body1 productDescription_productTitle__lpzz8 css-9l3uo3\"\u003eWarnings\u003c\/h2\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eWarning 1\u003c\/h3\u003e\n\u003cp\u003eAcute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists. After initiation of Tirzepatide, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain sometimes radiating to the back).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eWarning 2\u003c\/h3\u003e\n\u003cp\u003ePatients receiving Tirzepatide in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eWarning 3\u003c\/h3\u003e\n\u003cp\u003eIf hypersensitivity reactions occur, discontinue use of Tirzepatide; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity reaction to Tirzepatide or to any of the excipients used in Tirzepatide Injection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"ADDITIONAL INFORMATION\" class=\"productDescription_descriptionWrapper2__mjUHQ\"\u003e\n\u003ch2 class=\"MuiTypography-root MuiTypography-body1 productDescription_productTitle__lpzz8 css-9l3uo3\"\u003eAdditional Information\u003c\/h2\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003ePregnancy category\u003c\/h3\u003e\n\u003cp\u003eAlways consult your physician before using any medicine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"productDescription_descriptionWrapper3___ZqGB\"\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003eStorage (YES\/NO)\u003c\/h3\u003e\n\u003cp\u003eStore this medicine at room temperature, away from direct light and heat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"MuiTypography-root MuiTypography-body1 productDescription_productSubTitle__y_nDL css-9l3uo3\"\u003e\u003c\/h3\u003e\n\u003c\/div\u003e","brand":"Getz Pharma Pakistan (Pvt) Ltd.","offers":[{"title":"3800","offer_id":47763539165420,"sku":null,"price":3800.0,"currency_code":"PKR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0713\/3616\/5612\/files\/Untitleddesign-2026-06-19T133333.187.jpg?v=1781858033","url":"https:\/\/pillbox.pk\/ur\/products\/tirzee-injection-2-5mg-0-5ml-1-box-1prefilled-pen","provider":"PILLBOX+","version":"1.0","type":"link"}